| Asciminib studied in …STUDIED_INderived27 of 27show fewer |
|---|
| → studied in | NCT06236724Phase 2 · recruiting Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. · 27 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06308588Phase 1/Phase 2 · recruiting Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia · 27 trials list this drug (16 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06629584Phase 2 · recruiting Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia · 27 trials list this drug (16 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07039760early Phase 1 · not yet recruiting Asciminib With or Without Sildenafil for Brain Tumors · 27 trials list this drug (16 active) | — | — | Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04971226Phase 3 · active not recruiting A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · 27 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07789574Phase 2 · active not recruiting Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations · 27 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05456191Phase 3 · active not recruiting A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) · 27 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04838041Phase 2 · recruiting Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation · 27 trials list this drug (16 active) | — | — | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07604233Phase 1/Phase 2 · not yet recruiting Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML · 27 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03106779Phase 3 · completed Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs · 27 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03906292Phase 2 · active not recruiting Frontline Asciminib Combination in Chronic Phase CML · 27 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03874858Phase 2 · terminated A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia · 27 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07040982Phase 1 · recruiting Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · 27 trials list this drug (16 active) | — | — | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06427811Phase 4 · completed Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation · 27 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05413915Phase 3 · terminated Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML · 27 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03578367Phase 2 · completed Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. · 27 trials list this drug (16 active) | — | — | Leukemia,Myeloid Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06368414Phase 2 · recruiting A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia · 27 trials list this drug (16 active) | — | — | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07250087Phase 1 · recruiting Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL · 27 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04948333Phase 3 · completed Asciminib Treatment Optimization in ≥ 3rd Line CML-CP · 27 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04216563Phase 2 · terminated ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor · 27 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04360005available Managed Access Programs for ABL001, Asciminib · 27 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03595917Phase 1 · recruiting ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML · 27 trials list this drug (16 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04666259Phase 3 · completed Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation · 27 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05384587Phase 2 · active not recruiting Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia · 27 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06409936Phase 2 · recruiting PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML · 27 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive,Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04795427Phase 2 · completed Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors · 27 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02081378Phase 1 · completed A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL · 27 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |